Detalhe da pesquisa
1.
Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
Blood
; 140(6): 619-629, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560156
2.
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia.
Haematologica
; 108(2): 457-471, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950535
3.
CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
Blood Adv
; 7(16): 4418-4430, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171449
4.
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Cell Rep Med
; 4(11): 101290, 2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992684
5.
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Blood Cancer Discov
; 3(2): 103-115, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015683
6.
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
J Immunother Cancer
; 9(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531250